Guest guest Posted November 4, 2010 Report Share Posted November 4, 2010 November 2, 2010................... " Teflaro is a member of the cephalosporin class of antibiotics, the most frequently prescribed class of antibiotics in the world. Forest expects Teflaro to be available to wholesalers by January 2011. " Forest recognizes the enormous burden of disease associated with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, and we are extremely pleased to see that our first product in this category has obtained approval for both of these disease indications, " said Dirk Thye, President of Cerexa, a wholly-owned subsidiary of Forest Laboratories, Inc. " We eagerly anticipate the commercial launch of Teflaro and remain committed to bringing additional new treatments to market that target infectious diseases. " " , Chairman and Chief Executive Officer of Forest said, " Our success in gaining approval for Teflaro is a significant milestone for our new anti-infective franchise. Achieving a first cycle approval from the FDA is a tribute to the excellent design and execution of a complex clinical development program as well as the virtues of the product itself. Teflaro is the fourth new drug approval in the last three years from the fourth different division of the FDA. We are very proud of all of our Forest colleagues who have contributed to Teflaro's acquisition, development and approval. We look forward to providing more treatment options for healthcare providers and patients in the future. " http://www.medicalnewstoday.com/articles/206333.php FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.